Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The report details a specific share repurchase transaction executed on July 3, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 715,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,667 pence per share; lowest price paid was 1,647.50 pence per share.
- Treasury Holdings (Settled): 500,304,512 shares (9.25% of total issued share capital).
- Treasury Holdings (Including Unsettled): 502,439,512 shares (10.23% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,910,058,709 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 715,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 9.25% of issued capital and 10.23% of total voting rights when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares held in Treasury (500,304,512 settled) against the company's latest capitalization table.
- Confirm the denominator for voting rights calculations is 4,910,058,709 shares (excluding Treasury) for Disclosure and Transparency Rule notifications.
- Note that the filing does not contain operational or financial performance data for the period.